Norton, E. B., Branco, L.M. Clements, J.D. Evaluating the A-subunit of the heat-labile toxin (LT) as an immunogen and a protective antigen against enterotoxigenic Escherichia coli (ETEC). PLoS One. 2015 Aug 25;10(8):e0136302. doi: 10.1371/journal.pone.0136302. eCollection 2015. PMID: 26305793


Norton E. B., Bauer D.L., Weldon W.C., Oberste M.S., Lawson L.B., Clements J.D. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 2015;33(16):1909-15. doi: 10.1016/j.vaccine.2015.02.069. PubMed PMID: 25765967.

Read, L.T., Hahn, R.W., Thompson, C.C., Bauer, D.L., Norton, E.B., Clements, J.D. Simultaneous exposure to Escherichia coli heat-labile and heat-stable enterotoxins increases fluid secretion and alters cyclic nucleotide and cytokine production by intestinal epithelial cells. Infect Immun. 2014; 82(12):5308-16. PMID: 25483682


White, J.A., Blum, J.S., Hosken, N.A., Marshak, J.O., Duncan, L., Zhu, C., Norton, E.B., Clements, J.D., Koelle D.M., Chen, D., Lal, M. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Hum Vaccin Immunother. 2014 Nov:10(12). PMID: 25483682.


Tomchuck, S.L., Norton, E.B., Garry, R.F., Bunnell, B.A., Morris, C.A., Freytag, L.C., Clements, J.D. Mesenchymal Stem Cells as a Novel Vaccine Platform. Front Cell Infect Microbiol. 2012 Nov 2: 140. PMID: 23162801.


Norton, E. B., L. B. Lawson, Mahdi, Z., Freytag, L.C., Clements, J.D. The A-subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA and Th17 responses to vaccine antigens. Infect Immun. 2012 Jul;80(7):2426-35. PMID: 22526674


Lawson, L.B., Norton, E.B., Clements, J.D. Defending the Mucosa: Adjuvant and Carrier Formulations for Mucosal Immunity. Curr Opin Immunol. 2011 Jun;23(3):414-20. PMID: 21511452.


Cross R.W., Betancourt, A.M., Schur, M.J., Norton, E.B., Roy D, et al. Impact of Primary Influenza Infection on the Immune Response to Secondary Bacterial Infection in Aged Mice. Symposium on viral respiratory disease surveillance. Influenza and Other Respiratory Viruses.2011 May. (Suppl. 1), 195–201.


Norton, E. B., L. B. Lawson, Freytag, L. C., Clements, J.D. 2011. Characterization of a Mutant Escherichia coli Heat-labile Toxin, R192G/L211A, as a Safe and Effective Oral Adjuvant. Clin Vaccine Immunol. 2011 Apr;18(4):546-51. PMID: 21288994.


Norton, E., Clements, J, Voss, T., Freytag, L. Prophylactic Administration of Bacterially Derived Immunomodulators Improves the Outcome of Influenza Virus Infection in a Murine Model. J Virol. 2010 Mar; 84(6):2983-95. PMID: 20053748


Norton, E.B. Evaluation of Vaccine Adjuvants as Immunomodulators in Pulmonary Disease. Dissertation Thesis. 2009.

Norton, E., Archibald, L. K., Nwanyanwu, O. C., Kazembe, P. N., Dobbie, H., Reller B.R., Jarvis, W. R Jason, J. Clinical Predictors of Bloodstream Infections and Mortality in Hospitalized Malawian Children. Pediatr Infect Dis J. 2004 Feb;23(2):145-51. Discussion 151-5. PMID: 14872181

Jason, J., Archibald, L. K., Nwanyanwu, O. C., Kazembe, P. N., Chatt, J. A., Norton, E., Dobbie, H., Jarvis, W. R. Clinical and Immune Impact of Mycobacterium bovis BCG Vaccination Scarring. Infect Immun. 2002 Nov;70(11):6188-95.

For more information, visit Dr. Norton’s MyBibliography page.



Comments are closed